Merck & Co., Inc: Schizophrenia trials
The registry lists 15 Schizophrenia studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 12 have results posted.
Phase 1 8Phase 2 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)CompletedNCT05953740Phase 1Results posted
- A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)CompletedNCT05893862Phase 1Results posted
- A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)CompletedNCT05406440Phase 1Results posted
- Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)CompletedNCT05136690Phase 1Results posted
- Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)CompletedNCT04624243Phase 2Results posted
- Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)CompletedNCT04506905Phase 1Results posted
- A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)CompletedNCT03565068Phase 1Results posted
- An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)CompletedNCT03055338Phase 2Results posted
- Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)CompletedNCT02181803Phase 1Results posted
- Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)CompletedNCT00848484Phase 2Results posted
- A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)CompletedNCT00827918Phase 2Results posted
- Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)CompletedNCT00725075Phase 2Results posted
- Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)WithdrawnNCT00988728Phase 2
- Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)CompletedNCT00934466Phase 1
- MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)CompletedNCT00482430Phase 2